Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Br J Cancer · 2018 · PMC6219495 · PMID 30356126

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A recent large study using the pooled PORTEC biobank in which LVSI was quantified and graded as absent, mild (a single focus or few foci) or substantial (diffuse or multifocal) showed that substantial LVSI is a highly significant risk factor for pelvic and distant recurrence 14 .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.